|Bid||97.60 x 800|
|Ask||99.90 x 1000|
|Day's Range||90.00 - 98.80|
|52 Week Range||75.81 - 100.03|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2018 - Aug 6, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||114.14|
BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.
After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.
SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with achondroplasia, the most common form of disproportionate short stature in humans. "Vosoritide represents an innovative therapy to treat the underlying cause of achondroplasia. At the molecular level, vosoritide corrects the signaling process that determines skeletal growth and proportionality of bones, while the body is still growing," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
SAN RAFAEL, Calif. , June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc. These milestone ...
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies based on Targeted Protein Therapeutics platform for the treatment of patients with cancer. The stock jumped ~26.1% to $2.27 yesterday. The above chart shows analysts’ recommendations for Sesen Bio over the last three months. The stock price has increased ~37.6% in last three trading sessions. It has increased by ~68.8% over the last 12 months and 201.8% year-to-date. On May 30, Sesen Bio announced the pricing of the underwritten public offering of ~22.2 million shares of its common stock at $1.80 per share, the closing price on May 30.
The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.
Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.
Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.
Critics targeted the company's spending over 10 years of research and development on a drug that treats a rare, brain-damaging inherited disease. It was an emotional moment last week when the drug won approval.
In this updated daily bar chart of BMRN, below, we can see that the broader sideways trading range is still in place but in the past month BMRN has stayed above both the rising 50-day average line and the now rising 200-day line. The daily On-Balance-Volume (OBV) line has been steady this month and volume has recently increased. The trend-following Moving Average Convergence Divergence (MACD) oscillator dipped a little but is turning upwards again.
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.
NEW YORK, NY / ACCESSWIRE / May 29, 2018 / Ultragenyx Pharma shares jumped after announcing its clinical trial results for Crysvita® ( burosumab), while BioMarin Pharma earned approval for its Palynziq™ ...
BioMarin Pharmaceutical spiked to a 16-week high Friday after it gained approval for a rare-disease drug and priced it about 50% higher than analysts expected.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Here are the biotech stocks that were hitting 52-week highs May 24: ArQule, Inc. (NASDAQ: ARQL ) Baxter ...
This North Bay rare disease drug developer won its seventh regulatory approval, a potential replacement for one of its oldest (and most financially successful) drugs.
Check the Stock Market Today column to spot changes in market trend and track the best stocks to buy and watch.
In the first quarter, Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% YoY (year-over-year) to $144.4 million from $145.3 million. Analysts expect its revenue to grow 30.2% YoY to $135.7 million in the second quarter. The graph below compares Ionis’s revenue since Q1 2017.